BioDiscovery

NEW YORK (GenomeWeb News) – BioDiscovery and N-of-One today announced a marketing agreement to provide genomic analysis interpretation solutions.

GenBank 200.0 is now available from the National Center for Biotechnology Information via ftp.

Affymetrix and BioDiscovery this week announced the availability of Nexus for OncoScan Software for the analysis of whole-genome copy number data generated from formalin-fixed, paraffin-embedded solid tumor samples using Affy's OncoScan FFPE Expr

This week, Affymetrix and BioDiscovery jointly launched Nexus for OncoScan, a tool based on BioDiscovery's Nexus Copy Number software for customers of Affymetrix's OncoScan FFPE Express 2.0 Service, which generates whole genome copy number data f

Hawthorne, Calif.-based BioDiscovery has launched a software donation program aimed at assisting scientists studying pediatric diseases.

NEW YORK (GenomeWeb News) – Enigma Diagnostics this week said that it has received a Biomedical Catalyst grant from the UK government to support further development of multiplexed PCR assays using the firm's ResonSense probing technology.

NEW YORK (GenomeWeb News) – Agilent Technologies today announced a deal with BioDiscovery allowing that firm's customers access to Agilent SureFISH probes directly from BioDiscovery's Nexus software.

NEW YORK (GenomeWeb News) – Bioinformatics firm BioDiscovery and the Autism Genetic Resource Exchange today announced a co-marketing agreement that allows AGRE to provide copy number and allelic event data to its researchers through BioDiscovery's Nexus DB platform.

New Product Watch

Premium

Phalanx Biotech has updated its OneArray microRNA expression-profiling microarrays to reflect the content of miRBase version 17.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.